Hybio Files First Domestic Marketing Application for Tirzepatide Injection in China
On August 7, Hybio Pharmaceutical announced that it had recently received an Acceptance Notice from the National Medical Products Administration for its Tirzepatide Injection. At present, only Eli Lilly's imported product and its locally produced version are available for sale in China. Hybio is the first domestic company to submit a marketing authorization application for the drug.
Why this event matters
The event has a measured impact on 2 industrys. The strongest current signal is positive for Pharmaceuticals, with intensity 50/100 and 70% confidence over a short term horizon.
Healthcare · 13.1
Pharmaceuticals
- Direction
- positive
- Intensity
- 50
- Confidence
- 70%
- Horizon
- Short term
Biotechnology
- Direction
- positive
- Intensity
- 40
- Confidence
- 65%
- Horizon
- Short term
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.